The UK government has terminated its COVID-19 vaccine contract with Valneva over alleged breach of obligations, the company said on Monday.
The French biotech company said in a statement that it “has received a termination notice from the UK government (” HMG “) in connection with the supply agreement for its OVID-19 vaccine candidate.”
“HMG has alleged that the Company will be in breach of its obligations under the supply contract, but the Company strongly denies this,” he added.
Euronews has contacted the UK Department of Health for comment.
Britain ordered 100 million doses of Valneva’s vaccine candidate, VLA2001, and had the option of obtaining an additional 90 million doses. The total value of these 190 million doses is around 1.4 billion euros.
The jab is currently in phase 3 – meaning it’s tested for effectiveness on thousands of people – and results should be available early in the fourth trimester. Marketing is therefore planned before the end of the year.
The company began submitting its vaccine data for approval to the UK Medicines and Health Products Regulatory Agency (MHRA) last month and production of the vaccine began earlier in the year at a manufacturing facility in Scotland “to optimize the timing of potential vaccine deliveries.”
VLA2001 is an inactivated, adjuvanted vaccine that consists of whole inactivated SARS-CoV-2 virus particles mixed with two adjuvants to increase antibody levels. According to the company, the vaccine should meet standard cold chain requirements (2-8 ° C).
The UK regulator has so far approved four jabs from Oxford / AstraZeneca, Pfizer / BioNTech, Moderna and Janssen.
More than 89% of the UK population over 16 has so far received at least one dose of a vaccine and 80.9% are fully vaccinated.